TrialStat EDC

Fast, Compliant, Fully Unified – EDC + IWRS + ePRO + Coding

TrialStat Portal

Real-Time Data & Analytics | Make Study Decision Sooner

Don't Settle For Standard EDC Technology & Services

With TrialStat EDC you'll have your studies up and running quicker, capture your study data more efficiently with fewer errors and reduce your overall study costs.

We're Supporting COVID-19 Research

In times of crisis we all need to step up and help. Effective immediately, we are offering TrialStat’s eClinical Platform and Data Analytics Portal at discounted rates to researchers working on solutions related to COVID-19. With a focus on ease of use, speed of implementation, and real-time data analytics, TrialStat’s data capture suite enables fast study start up and ensures all stakeholders have relevant, customized, timely insight into all aspects of study data and areas of risk or potential delays. We welcome the opportunity to collaborate with our industry colleagues on the path to treatments or cures – please contact [email protected] to learn more about this program.

Have questions about enrolling in a clinical trial, or about the COVID-19 Vaccines?

If you're a member of the general public and have questions about the approved vaccines, or are interested in enrolling in a clinical trial please have a look at the following resources:

From the entire TrialStat team, we wish you and yours good health as our industry and our communities work together to navigate this outbreak over the coming weeks and months. Thank you for #StayingHome and #FlatteningTheCurve!


Our Latest COVID-19 Research News

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19

Excerpt from the Press Release: BOSTON, April 29, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), ...
Read More

Good Isn’t Good Enough: Moderna Continues Efforts to Improve COVID-19 Vaccine

Excerpt from the Article: Moderna, one of three companies to have a COVID-19 vaccine authorized in the U.S., ...
Read More

Valneva Initiates Pivotal Phase 3 Clinical Trial for its Inactivated, COVID-19 Vaccine Candidate using Dynavax’s CpG 1018™ Adjuvant

Excerpt from the Press Release: EMERYVILLE, Calif., April 21, 2021 /PRNewswire/ -- DYNAVAX TECHNOLOGIES CORPORATION (Nasdaq: DVAX), a biopharmaceutical company focused on developing ...
Read More

Clinical Trial Restart Resource Toolkit

Clinical Trials Ontario has released a Clinical Trial Restart Toolkit! "This toolkit provides a collection of best practices, ...
Read More

How mRNA Vaccines Could Prevent or Eliminate Infectious Diseases Beyond COVID-19

Excerpt from the Article: COVID-19 vaccines have quickly come to the rescue. Scientists created a vaccine to prevent ...
Read More

Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Second Interim Results demonstrating 100% Protection against Severe Disease including Hospitalization

Excerpt from the Press Release: MALVERN, Pa., April 21, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company ...
Read More

Translate Bio Announces Publication of Preclinical Results of COVID-19 mRNA Vaccine Candidate MRT5500 in npj Vaccines

Excerpt from the Press Release: LEXINGTON, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a ...
Read More

Scientists Reverse Engineer mRNA Sequence of Moderna Vaccine

Excerpt from the Article: Leftover drops in vials of Moderna’s COVID-19 vaccine allowed a group of researchers from ...
Read More

Moderna Highlights Publication of Antibody Persistence Data of its COVID-19 Vaccine out to 6 Months in the New England Journal of Medicine

Excerpt from the Press Release: CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) ...
Read More